// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

CHROMOTHRIPSIS IN PATIENTS WITH CLL AND COMPLEX KARYOTYPE: PATTERNS OF ABERRATIONS AND PROGNOSTIC VALUE

Silvia Ramos-Campoy - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY

Andrew Brunner - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Chronic myelomonocytic leukemia

AZD6738

EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT

David Kuter - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

LOW EXPRESSION OF C-TYPE LECTIN-LIKE MOLECULE-1 AND REDUCED OXIDATIVE STRESS DEFINE A SUBSET OF ACUTE MYELOID LEUKAEMIA CELLS WITH ‘STEM-LIKE' PROPERTIES

Kim Sharp - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL

Paolo Ghia - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Bendamustine

INHIBITION OF CKS1-DEPENDENT PROTEOSTASIS REVEALS VULNERABILITIES IN LEUKAEMIC STEM CELLS WITH CONCOMITANT PROTECTION OF HEALTHY HAEMATOPOIETIC STEM CELLS

William Grey - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH ZANUBRUTINIB VS IBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (RR) CLL/SLL: RESULTS FROM THE RANDOMIZED PHASE 3 ALPINE TRIAL

Peter Hillmen - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Ibrutinib

EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY

Veronique Minard-Colin - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

B-Cell Non-Hodgkin Lymphoma

Cyclophosphamide

LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

Kevin H. M. Kuo - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Beta-thalassemia

Adenosine-5'-triphosphate

NON-HEMATOLOGICAL MALIGNANCIES IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE PATIENTS: A MATCHED COHORT ANALYSIS USING A HEALTH CLAIMS-BASED DATASET

Sudipto Mukherjee - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

ILS-969

ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS.

Hege Garelius - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Erythropoietin

MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR

Srdan Verstovsek - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

Momelotinib

MYBLOCK: A MYELOID BLOOD CANCER INITIATIVE

Lauren Cairns - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

N/A

NEOANTIGENS PREDICTED BY THE GNE NEOANTIGEN PIPELINE IN PATIENTS DIAGNOSED WITH DE NOVO MULTIPLE MYELOMA

Yanrong Jiang - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

GENOMIC CHARACTERISATION OF B-OTHER ALL IN UKALL2003 PATIENTS BY NEXT GENERATION SEQUENCING

Claire Schwab - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-cell acute lymphoblastic leukemia

N/A

TREATING BING-NEEL SYNDROME USING A TAILORED APPROACH: EXPERIENCE OF A SPECIALIST NEUROHAEMATOLOGY CLINIC

Jahanzaib Khwaja - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

IMMUNE RECONSTITUTION AFTER BMT FOR NON-MALIGNANT HEMATOLOGICAL CONDITIONS FOR RELATED, UNRELATED AND HAPLOIDENTICAL DONORS. A STUDY IN THE PEDIATRIC DEPARTMENT AT ST MARY'S HOSPITAL BETWEEN 2019&2020

Ahmad Khoder - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Alemtuzumab

UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

Joaqun Martnez-Lpez - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Multiple Myeloma

N/A

HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE

Arnaud Jaccard - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

AL Amyloidosis

N/A

RISK FACTORS AND OUTCOMES OF PATIENTS WITH HAEMATOLOGICAL MALIGNANCY AND COVID-19: ONGOING REDUCTION IN MORTALITY DURING THE 3RD WAVE OF THE PANDEMIC

Jamie Maddox - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Copyright © 2026. QuantiNova All rights reserved